StockData
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

INTENSITY THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.29−0.06 (-1.79%)

Close on Oct 19, 2026

Market cap
$8.90M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026Before market open–$-1.11–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026During market hours–$-0.96–
Q4 FY2025
Ended Dec 31, 2025
Mar 27, 2026During market hours–––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025During market hours–$-0.06–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours–$-0.13–
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025During market hours–$-0.22–
Q4 FY2024
Ended Dec 31, 2024
Mar 13, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024During market hours–$-0.25–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024During market hours–$-0.36–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024During market hours–$-0.34–
Q4 FY2023
Ended Dec 31, 2023
Mar 14, 2024During market hours–––

Press releases

Announcements Intensity Therapeutics filed with the SEC